Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01441375 · ClinicalTrials.gov registry record
Sickle Cell Disease: A Retrospective Chart Review
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 261
- Enrollment target
NCT01441375: Completed study, sponsored by Novartis Pharmaceuticals.
NCT01441375 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 261 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01441375 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 261 participants
- Enrollment target
Study Summary
This study is a retrospective chart review of sickle cell patients and will include patients whom have received blood transfusions and those whom have not. Of the transfused patients, it will also include those whom have received chelation therapy and those whom have not.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2011-07 |
| Est. Completion | 2012-07 |
What the finished NCT01441375 record still lists
NCT01441375 is an observational study that tracks outcomes without assigning an intervention. The registered 261 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01441375 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01441375 about?
NCT01441375 is a clinical study titled "Sickle Cell Disease: A Retrospective Chart Review". This study is a retrospective chart review of sickle cell patients and will include patients whom have received blood transfusions and those whom have not. Of the transfused patients, it will also include those whom have received chelation therapy and those whom have not.
What is the current status of trial NCT01441375?
This trial is currently completed. The enrollment target is 261 participants. The study started on 2011-07. Estimated completion is 2012-07.
Who is sponsoring clinical trial NCT01441375?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05124912 · 261 participants · NA
REMASTer: REcurrent Brain Metastases After SRS Trial
- NCT06559891 · 261 participants · NA
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
- NCT03713268 · 262 participants
Intraoperative OCT Guidance of Intraocular Surgery II
- NCT06074380 · 262 participants · Phase 4
Non Inferiority Trial Investigating Surfactants Administered Via MIST
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia